|
2025 Conference Publication 2D and 3D spatial characterisation of tertiary lymphoid structures in head and neck cancer patients receiving immune checkpoint blockade therapyDonovan, Meg L., Sadeghirad, Habib, Berrell, Naomi, Monkman, James, Naei, Vahid Yaghoubi, Tan, Chin Wee, Yunis, Joseph, West, Zoe, Warkiani, Majid E., Ladwa, Rahul, Hughes, Brett G., Da Gama Duarte, Jessica and Kulasinghe, Arutha (2025). 2D and 3D spatial characterisation of tertiary lymphoid structures in head and neck cancer patients receiving immune checkpoint blockade therapy. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-5252 |
|
2025 Conference Publication Exploring PD1/PDL1 interactions and macrophage-tumor barriers in head and neck cancer: A spatial approach to immunotherapy responseNaei, Vahid Yaghoubi, Tubelleza, Rafael, Monkman, James, Sadeghirad, Habib, Donovan, Meg L., Blick, Tony, Wicher, Agata, Bodbin, Sara, Basu, Subham, Stad, Robert, Barnett, Catherine, O’Byrne, Ken, Ladwa, Rahul, Cooper, Caroline, Warkiani, Majid Ebrahimi, Hughes, Brett G.M. and Kulasinghe, Arutha (2025). Exploring PD1/PDL1 interactions and macrophage-tumor barriers in head and neck cancer: A spatial approach to immunotherapy response. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-750 |
|
2025 Journal Article Survival after orbital exenteration for primary cutaneous squamous cell carcinoma: a retrospective cohort studyMurray-Douglass, Alexander, Crawford, Lachlan, Hunt, Justin, Dunn, Darryl, Hughes, Brett G. M., Lin, Charles and Fox, Carly (2025). Survival after orbital exenteration for primary cutaneous squamous cell carcinoma: a retrospective cohort study. Annals of Surgical Oncology, 32 (4) i3, 2725-2731. doi: 10.1245/s10434-024-16854-w |
|
2025 Journal Article ASO Visual Abstract: Survival Following Orbital Exenteration for Primary Cutaneous Squamous Cell Carcinoma, a Retrospective Cohort StudyMurray-Douglass, Alexander, Crawford, Lachlan, Hunt, Justin, Dunn, Darryl, Hughes, Brett G. M., Lin, Charles and Fox, Carly (2025). ASO Visual Abstract: Survival Following Orbital Exenteration for Primary Cutaneous Squamous Cell Carcinoma, a Retrospective Cohort Study. Annals of Surgical Oncology, 32 (5), 3485-3486. doi: 10.1245/s10434-025-16995-6 |
|
2025 Journal Article Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy responseNaei, Vahid Yaghoubi, Tubelleza, Rafael, Monkman, James, Sadeghirad, Habib, Donovan, Meg L., Blick, Tony, Wicher, Agata, Bodbin, Sara, Viratham, Amelie, Stad, Robert, Basu, Subham, Cooper, Caroline, Barnett, Catherine, O’Byrne, Ken, Ladwa, Rahul, Warkiani, Majid Ebrahimi, Hughes, Brett G. M. and Kulasinghe, Arutha (2025). Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response. Journal of Translational Medicine, 23 (1) 177, 1-15. doi: 10.1186/s12967-025-06186-y |
|
2025 Journal Article Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation–positive NSCLC: an open-label phase 2 trial (ILLUMINATE)Lee, Chee Khoon, Liao, Bin-Chi, Subramaniam, Shalini, Chiu, Chao-Hua, Mersiades, Antony J., Ho, Chao-Chi, Brown, Chris, Lai, Chun-Liang, Hughes, Brett G. M., Yang, Tsung-Ying, O'Byrne, Ken, Luo, Yung-Hung, Yip, Sonia, Ho, Ching-Liang, Bray, Victoria, Su, Wu-Chou, Moore, Melissa, Feng, Wei-Lien, Bai, Ya-Ying, Ford, Kate, Cummins, Michelle M., Stockler, Martin R., Solomon, Benjamin J., John, Thomas and Chih-Hsin Yang, James (2025). Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation–positive NSCLC: an open-label phase 2 trial (ILLUMINATE). JTO Clinical and Research Reports, 6 (2) 100771, 100771. doi: 10.1016/j.jtocrr.2024.100771 |
|
2025 Journal Article Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapyChin, Wee Loong, Cook, Alistair M., Chee, Jonathan, Principe, Nicola, Hoang, Tracy S., Kidman, Joel, Hmon, Khaing P.W., Yeow, Yen, Jones, Matthew E., Hou, Rui, Denisenko, Elena, McDonnell, Alison M., Hon, Chung-Chau, Moody, Jonathan, Anderson, Denise, Yip, Sonia, Cummins, Michelle M., Stockler, Martin R., Kok, Peey-Sei, Brown, Chris, John, Thomas, Kao, Steven C.-H., Karikios, Deme J., O'Byrne, Kenneth J., Hughes, Brett G.M., Lake, Richard A., Forrest, Alistair R.R., Nowak, Anna K., Lassmann, Timo and Lesterhuis, W. Joost (2025). Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy. Cell Reports Medicine, 6 (1) 101882, 1-18. doi: 10.1016/j.xcrm.2024.101882 |
|
2025 Journal Article Type I interferon drives a cellular state inert to TCR-stimulation and could impede effective T-cell differentiation in cancerCorvino, Dillon, Batstone, Martin, Hughes, Brett G. M., Kempchen, Tim, Ng, Susanna S., Salim, Nazhifah, Schneppenheim, Franziska, Rommel, Denise, Kumar, Ananthi, Pearson, Sally, Madore, Jason, Koufariotis, Lambross T., Steinheuer, Lisa Maria, Pathirana, Dilan, Thurley, Kevin, Hölzel, Michael, Borcherding, Nicholas, Braun, Matthias and Bald, Tobias (2025). Type I interferon drives a cellular state inert to TCR-stimulation and could impede effective T-cell differentiation in cancer. European Journal of Immunology, 55 (1) e202451371, 1-13. doi: 10.1002/eji.202451371 |
|
2025 Journal Article Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinomaMachiels, J. P., Tao, Y., Licitra, L., Burtness, B., Tahara, M., Rischin, D., Alves, G. V., Lima, I. P.F., Hughes, B. G.M., Pointreau, Y., Aksoy, S., Laban, S., Greil, R., Burian, M., Hetnal, M., Delord, J. P., Mesia, R., Taberna, M., Waldron, J., Simon, C., Gregoire, V., Harrington, K., Black, C. M., Norquist, J. M., Wang, A., Gumuscu, B., Bidadi, B. and Siu, L. L. (2025). Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. Frontiers in Oncology, 15 1645509. doi: 10.3389/fonc.2025.1645509 |
|
2025 Journal Article A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6Hughes, Brett G.M., Guminski, Alexander, Bowyer, Samantha, Migden, Michael R., Schmults, Chrysalyne D., Khushalani, Nikhil I., Chang, Anne Lynn S., Grob, Jean-Jacques, Lewis, Karl D., Ansstas, George, Day, Fiona, Ladwa, Rahul, Stein, Brian N., Muñoz Couselo, Eva, Meier, Friedegund, Hauschild, Axel, Schadendorf, Dirk, Basset-Seguin, Nicole, Modi, Badri, Dalac-Rat, Sophie, Dunn, Lara A., Flatz, Lukas, Mortier, Laurent, Guégan, Sarah, Heinzerling, Lucie M., Mehnert, Janice M., Trabelsi, Sabiha, Soria-Rivas, Ainara, Stratigos, Alexander J. ... Rischin, Danny (2025). A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6. Journal of the American Academy of Dermatology, 92 (1), 68-77. doi: 10.1016/j.jaad.2024.06.108 |
|
2024 Journal Article Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort studyChow, Kar Ven Cavan, Turner, Cassie, Hughes, Brett, Lwin, Zarnie and Chan, Bryan (2024). Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort study. Asia-Pacific Journal of Clinical Oncology, 20 (6), 723-730. doi: 10.1111/ajco.14098 |
|
2024 Journal Article Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patientsZhang, Xi, Weeramange, Chameera Ekanayake, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz, Breik, Omar and Punyadeera, Chamindie (2024). Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients. Cellular and Molecular Life Sciences, 81 (1) 233, 1-14. doi: 10.1007/s00018-024-05269-1 |
|
2024 Journal Article Revalidation of proactive gastrostomy tube placement guidelines for head and neck cancer patients receiving helical intensity-modulated radiotherapyBrown, Teresa E., Byrnes, Angela, Chan, Aaron C., Dwyer, Kathleen, Edwards, Anna, Blake, Claire L., Banks, Merrilyn D., Hughes, Brett G. M., Lin, Charles Y., Kenny, Lizbeth M., Spurgin, Ann-Louise and Bauer, Judith D. (2024). Revalidation of proactive gastrostomy tube placement guidelines for head and neck cancer patients receiving helical intensity-modulated radiotherapy. Current Oncology, 31 (11), 6938-6955. doi: 10.3390/curroncol31110512 |
|
2024 Journal Article Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 TrialAnnageldiyev, Charyguly, Gaudreau, Pierre-Olivier, Leitzel, Kim, Ali, Suhail M., Ding, Keyue, Leighl, Natasha B., Vera Badillo, Francisco Emilio, Bradbury, Penelope Ann, Goss, Glenwood D., Shepherd, Lois E., Costa, Luis, Suva, Larry J., Hughes, Brett G.M., Stockler, Martin R., Drabick, Joseph J., Ma, Patrick C., Joshi, Monika, Moku, Prashanth, Polimera, Hyma V., Louis, Patricia, Ramachandrula, Priya and Lipton, Allan (2024). Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial. JCO Oncology Advances (1). doi: 10.1200/oa.24.00017 |
|
2024 Journal Article Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy responseSadeghirad, Habib, Monkman, James, Tan, Chin Wee, Liu, Ning, Yunis, Joseph, Donovan, Meg L., Moradi, Afshin, Jhaveri, Niyati, Perry, Chris, Adams, Mark N., O’Byrne, Ken, Warkiani, Majid E., Ladwa, Rahul, Hughes, Brett G.M. and Kulasinghe, Arutha (2024). Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. Journal of Translational Medicine, 22 (1) 677, 677. doi: 10.1186/s12967-024-05409-y |
|
2024 Journal Article A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinomaLadwa, Rahul, Chandra, Janin, Woo, Wai-Ping, Finlayson, Neil, Liu, Howard, McGrath, Margaret, See, Adrienne, Hughes, Brett G., Cooper, Caroline L., Jackson, Jim E., Dzienis, Marcin, Xu, Yan, Panizza, Benedict, Frazer, Ian and Porceddu, Sandro V. (2024). A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma. Frontiers in Oncology, 14 1419258, 1-8. doi: 10.3389/fonc.2024.1419258 |
|
2024 Journal Article Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyCho, Byoung Chul, Braña, Irene, Cirauqui, Beatriz, Aksoy, Sercan, Couture, Felix, Hong, Ruey-Long, Miller, Wilson H., Chaves-Conde, Manuel, Teixeira, Margarida, Leopold, Lance, Munteanu, Mihaela, Ge, Joy Yang, Swaby, Ramona F. and Hughes, Brett G. M. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer, 23 (Suppl 1) 1254, 1-12. doi: 10.1186/s12885-023-11316-0 |
|
2024 Journal Article Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trialSolomon, Benjamin J., Dagogo-Jack, Ibiayi, Lee, Se-Hoon, Boyer, Michael J., Ramalingam, Suresh S., Carcereny, Enric, Felip, Enriqueta, Han, Ji-Youn, Hida, Toyoaki, Hughes, Brett G.M., Kim, Sang-We, Nishio, Makoto, Seto, Takashi, Okamoto, Tatsuro, Zhang, Xiaoxi, Martini, Jean-Francois, Wang, Erjian, De Beukelaer, Steven and Bauer, Todd M. (2024). Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trial. JTO Clinical and Research Reports, 5 (7) 100685. doi: 10.1016/j.jtocrr.2024.100685 |
|
2024 Conference Publication A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-SquamateLadwa, Rahul, Lee, Jenny H.J., Porceddu, Sandro V., McGrath, Margaret Louise, Cooper, Caroline, Liu, Howard, Gupta, Ruta, Cuscaden, Claire, Nottage, Michelle K., Clark, Jonathan, Le, Dieu, Pauley, Marketa, Gonzalez-Cruz, Jazmina, Frazer, Ian, Hughes, Brett Gordon Maxwell and Panizza, Benedict J. (2024). A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.9514 |
|
2024 Journal Article Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancerFelip, Enriqueta, Metro, Giulio, Tan, Daniel S.W., Wolf, Juergen, Mark, Michael, Boyer, Michael, Hughes, Brett G. M., Bearz, Alessandra, Moro-Sibilot, Denis, Le, Xiuning, Puente, Javier, Massuti, Bartomeu, Tiedt, Ralph, Wang, Yingying, Xu, Chao, Mardjuadi, Feby I. and Cobo, Manuel (2024). Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer. Lung Cancer, 192 107820, 107820. doi: 10.1016/j.lungcan.2024.107820 |
